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Abstract
Background: Allogeneic stem cell transplantation (allo-HCT) is associated with high treatment-related mortality and
innumerable physical and psychosocial complications and side-effects, such as high fatigue levels, loss of physical
performance, infections, graft-versus-host disease (GvHD) and distress. This leads to a reduced quality of life, not only
during and after transplantation, but also in the long term. Exercise interventions have been shown to be beneficial in
allo-HCT patients. However, to date, no study has focused on long-term effects and survival. Previous exercise studies
used ‘usual care’ control groups, leaving it unclear to what extent the observed effects are based on the physical effects
of exercise itself, or rather on psychosocial factors such as personal attention. Furthermore, effects of exercise on and
severity of GvHD have not been examined so far. We therefore aim to investigate the effects and biological mechanisms
of exercise on side-effects, complications and survival in allo-HCT patients during and after transplantation.
Methods/design: The PETRA study is a randomized, controlled intervention trial investigating the effects of a yearlong
partly supervised mixed exercise intervention (endurance and resistance exercises, 3–5 times per week) in 256 patients
during and after allogeneic stem cell transplantation. Patients in the control group perform progressive muscle relaxation
training (Jacobsen method) with the same frequency. Main inclusion criterion is planned allo-HCT. Main exclusion criteria
are increased fracture risk, no walking capability or severe cardiorespiratory problems. Primary endpoint is overall survival
after two years; secondary endpoints are non-relapse mortality, median survival, patient reported outcomes including
cancer related fatigue and quality of life, physical performance, body composition, haematological/immunological
reconstitution, inflammatory parameters, severity of complications and side-effects (e.g. GvHD and infections), and
cognitive capacity.
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Discussion: The PETRA study will contribute to a better understanding of the physiological and psychological effects
of exercise training and their biological mechanisms in cancer patients after allo-HCT. The ultimate goal is the
implementation of optimized intervention programs to reduce side-effects and improve quality of life and potentially
prognosis after allogeneic stem cell transplantation.
Trial registration: ClinicalTrials.gov Identifier: NCT01374399.
Background
Allogeneic stem cell transplantation (allo-HCT) is the
only curative medical treatment option for patients with
haematological malignancies in high-risk situations e.g.
acute leukaemia. However, patients suffer from numer-
ous treatment related side-effects and complications,
and the transplant-related mortality is high [1]. Exercise
constitutes a potentially promising intervention approach
for this patient group. Over the last years, several clinical
trials have contributed to the growing body of evidence
showing the beneficial effects of exercise in cancer pa-
tients [2–5], and some general exercise recommendations
for cancer patients have already been published [6] also in
the field of allo-HCT [7].
Our group has reviewed exercise intervention studies
in the context of stem cell transplantation and illustrated
that exercise interventions at different time points dur-
ing and after HCT might significantly improve physical
performance, quality of life, symptom control and fatigue
[7]. Since publication of this review, 6 new randomized
controlled trials (RCTs) have been published supporting
the findings [8–13]. These studies were included in a
recent review and meta-analysis by Persoon et al. [14]
and the authors found that exercise significantly improved
cardiorespiratory fitness, lower extremity muscle strength
and fatigue and had also a small effect on upper extremity
muscle strength, quality of life (QoL), physical, emotional
and cognitive function. The researcher concluded that
more high-quality studies were needed [14]. However, it is
still not possible to give patients clear advice regarding the
best type, intensity, start and duration of an exercise
program.
Prior to allo-HCT, patients’ physical performance is
already affected due to the disease itself and/or previous
treatment [15, 16]. Furthermore, emerging evidence in-
dicates that cancer patients have considerably impaired
cardiorespiratory fitness as a result of the toxic effects of
anticancer therapy or as a consequence of the disease
(for example cachexia, deconditioning, anaemia) [17].
Thus, physical activity levels have been described as gen-
erally low in a group of haematological cancer survivors
[18]. Furthermore, one study compared the quality of life
of 662 HCT survivors with age- and sex-matched healthy
controls and observed poorer general health, physical
function, well-being, depression, cognitive function, and
fatigue in HCT survivors [19]. A major complication after
allo-HCT is graft-versus-host disease (GvHD). GvHD is
the leading cause of morbidity and high transplant-related
mortality. It is characterized by a reaction of donor T-cells
against patient tissues e.g. mucosa or skin [1, 20]. More-
over, chronic GvHD is associated with a lower physical
performance and functional capacity [21]. A recent review
shows that patients after HCT are likely to have long-term
difficulties with physical functioning, problems with fatigue,
distress and a deteriorated psychological well-being [22].
Furthermore, patients after allo-HCT are at increased risks
of cardiovascular events and pulmonary complications
[23, 24].
Moreover, fatigue is a frequently reported adverse
side-effect in cancer patients [25]. One study described
the fatigue experience in allo-HCT patients during the
first 100 days. In this observation, 68 % reported fatigue
at the day of transplantation, 90 % at day 30 and 81 % at
day 100 after allo-HCT [26]. A Cochrane review and an
American College of Sports Medicine (ACSM) roundta-
ble concluded that exercise may be an effective treat-
ment against fatigue [2, 6]. Our recently published RCT
supports these finding by demonstrating positive effects
of exercise during and after allo-HCT on fatigue [13].
Mechanisms underlying the positive effect of exercise on
fatigue are not fully elucidated, current models favor
physiological and biological effects, for example enhanced
physical performance, reduced inflammation, and less dis-
tress [27, 28].
A recent Cochrane review aimed to evaluate the effects
of aerobic exercise in haematological malignancies. Exer-
cise improved quality of life, especially physical function-
ing, depression and fatigue. The authors emphasised that
none of the included studies investigated effects on sur-
vival. They concluded that trials with overall survival as
primary endpoint are needed [29]. So far, the evidence
regarding a possible influence of exercise on survival
after cancer diagnosis is limited. A recent review by
Ballard-Barbash et al. [30] found consistent evidence
from 27 observational studies, that physical activity is
associated with reduced all-cause, breast-cancer and
colon-cancer specific mortality, but evidence regard-
ing other cancers is currently insufficient [30]. Studies
suggest that cardio-respiratory fitness may be a robust
predictor of prognosis in non-small lung cancer patients
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and metastatic breast cancer [17, 31]. Courneya et al. [32]
presented for the first time data from a RCT in 242 breast
cancer patients, and found a non-significant trend for a
better outcome (overall survival and disease-free survival)
in the exercise group [32]. In addition, a small cohort
study with 22 patients showed that patients with low car-
diorespiratory fitness before allo-HCT had a higher risk of
mortality after allo-HCT [33], furthermore, in a prospect-
ive cohort study in allo-HCT patients, the Karnofsky
Performance Score (KPS) was an independent predictor of
survival, and KPS <90 % was a predictor of non-relapse
mortality (NRM) [34].
Data from our RCT in allo-HCT patients [13] also
suggest a potential effect of exercise on survival. We
observed a significantly reduced two-year total mortality
(TM) for the experimental group (12 vs. 28 %, p = .034)
after inpatient period. The effect was controlled for
major confounding factors (Gratwohl Score, KPS, condi-
tioning regime, gender, and fitness prior transplantation).
Similar results were observed for non-relapse mortality
(4 vs. 13 %, p = .017) when controlled for potential con-
founders. When we included the inpatient period, the
risk reductions were similar but not significantly differ-
ent. Interestingly, fitness at baseline was protective
against NRM (p > .001). These results are encouraging,
however, a major limitation of this study is that this was
a post-hoc analysis and the study was not powered for
the primary endpoint survival [35].
In consequence of the above mentioned findings, we
currently perform an RCT to investigate the effects and
biological mechanisms of a partly supervised yearlong
exercise training on prognosis, complications, side-effects
and biomarkers in patients during and after allo-HCT.
To determine the specific effect of the exercise inter-
vention itself beyond potential psychosocial effects,
patients in the control group receive a comparable
training schedule but with muscle relaxation according
to the Jacobsen method, and the same personal atten-
tion as the exercise group.
Methods/design
Study design
The PETRA study (acronym for Physical Exercise Train-
ing versus Relaxation in Allogeneic stem cell transplant-
ation) is a 12-month prospective, randomized, controlled
clinical intervention trial in patients during and after
allogeneic stem cell transplantation. Patients have to
provide written informed consent prior to participation
in the study. After baseline assessments, participants are
randomized to a mixed type exercise program (resistance
and endurance exercises) or a relaxation program over a
period of one year. Both interventions are administered
partly supervised. Endpoints are assessed before admission
to hospital (baseline, t0), at the day of discharge (t1), day
100 after transplantation (t2), and day 180, 270 and 365
post transplantation (t3, t4, t5). Follow-up measurement
will be 720 days after transplantation. [see Fig. 1].
The PETRA study has been approved by the ethic com-
mittees of the Ethic Committee II of the University of
Mannheim (number 2009–349 N-MA) and Heidelberg
University (number S-021/2011) and is registered at
ClinicalTrials.gov (NCT01374399).
Objectives
The primary objective of PETRA is to determine the
effect of exercise on 2-year overall- survival after allo-
HCT.
Secondary objectives are to estimate the effect of exer-
cise on 2-year non-relapse mortality, median survival,
fatigue, quality of life, physical fitness, including muscle
strength, cardio-respiratory fitness, and body compos-
ition as well as on cognitive function. The effects of
exercise on immunologic and inflammatory parameters
and factors relevant for cancer prognosis and GvHD will
be investigated and compared to the progressive muscle
relaxation group. Finally, the sustainability of the effects
will be assessed 720 days after allo-HCT.
Outcome measures
The outcome measures used in the PETRA study are
summarized in Table 1.
Primary outcome
Two-year overall survival data will be collected using med-
ical logs and will be approved by the study physician (PD).
Secondary outcomes
Non-relapse mortality and median survival
We will distinguish between 2-year non-relapse mortal-
ity (e.g. related to GvHD, sepsis), median survival and
median disease-free survival. Survival data will be col-
lected using medical logs and will be approved by the
study physician (PD).
Physical fitness
Muscle strength is assessed by measuring isometric
(4 positions) and isokinetic (1 angular velocity) max-
imal muscle capacity with the IsoMed 2000® diagnostic
module (isokinetic evaluation and training machine). The
protocol includes testing of representative muscle groups
for lower (knee extensors and flexors, hip flexor and
extensor) and upper (elbow flexor and extensor) extremity.
Reliability and validity of isokinetic dynamometer machines
have been reported in several studies [36–38]. Additionally,
a hand-held-dynamometer (C.I.T. Technics) is applied to
assess isometrically 6 different muscle groups within stan-
dardized test positions (knee-extensors, knee-flexors, hip-
abductors, hip-flexors, elbow-flexors and elbow-extensors)
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[39]. Each measurement is repeated 3 times, values that are
<10 % different from the median will be excluded. Hand-
held–dynamometers were already applied in hematological
cancer patients [13, 40, 41].
Endurance performance (maximum oxygen uptake,
VO2peak) is measured by performing a symptom-limited
maximal cardiopulmonary exercise test (CPET) with a
step protocol (starting at 50 watts with steps of 25 watts
every 2 min) on a bicycle ergometer. The criteria of
exhaustion is defined as achieved estimated maximum
heart rate, and respiratory exchange ratio >1.1. VO2peak
is defined as highest 30-s average during the test. Peak
workload, peak oxygen uptake and oxygen uptake and
workload at ventilatory threshold will be taken for ana-
lysis. Cardiorespiratory exercise testing is well estab-
lished in cancer patients and recommendations for
testing procedures as well as safety guidelines in clinical
trials with cancer populations exist [42–44]. Further-
more, the six-minute walk test is applied to measure
submaximal endurance performance. Heat rate and O2-
saturation is assessed before, during and after the test
and the individual perceived exhaustion is measured
using the RPE-Scale [45]. For reference values the for-
mula by Enright et al. [46] will be used. The six-minute
walk test was already applied in hematological cancer
patients [8, 13].
Body composition of the participants is estimated with
bioelectrical impedance analysis (BIA). This non-invasive
method determines the electrical impedance, or oppos-
ition to the flow of an electric current through body
tissues to calculate an estimate of total body water, fat-free
body mass and body fat [47]. BIA gives reliable measure-
ments of body composition with minimal intra- and inter-
observed variability [48]. In addition, body weight and
height are measured.
Accelerometer (ActiGraph GT3X) is used to assess
physical activity behavior. The ActiGraph is a triaxial
accelerometer, that records motion in different planes
and provides information about intensity, frequency
and duration of physical activity [49]. Patients will
wear the accelerometers during hospital stay for the
transplantation and at all measurement points (except
t1) for 10 days at home during daytime. Accelerome-
ters were already used in HCT patients [50].
Fig. 1 CONSORT: Study Flow of the PETRA study
Wiskemann et al. BMC Cancer  (2015) 15:619 Page 4 of 11
Quality of life (QoL)
QoL is assessed with the validated 30-item self-assessment
questionnaire of the European Organisation for Research
and Treatment of Cancer (EORTC QLQ-C30, version
3.0). It includes five multi-item functional scales (physical,
role, emotional, cognitive, and social function), three
multi-item symptom scales (fatigue, pain, nausea/
vomiting) and six single items assessing further symp-
toms (dyspnea, insomnia, appetite loss, constipation,
diarrhea) and financial difficulties [51]. In addition, the
29-item high-dose chemotherapy (EORTC QLQ-HDC-29)
is applied, assessing common problems after stem cell
transplantation, e.g. gastro-intestinal side-effects and
worry/anxiety [52]. Scores will be derived according to
the EORTC scoring manual. Reference values are available
from the EORTC reference manual, a review, including
2,800 patients before and after HCT [53] and from a sam-
ple of the general German population stratified by gender
and age [54]. Furthermore, evidence-based guidelines for
the interpretation of the clinical relevance of changes in
the different EORTC QLQ-C30 subscales were recently
published [55], categorizing differences between scores in
trivial, small, medium or large effect sizes.
Fatigue
Fatigue will be assessed with the Multidimensional Fatigue
Inventory (MFI) which is a 20-item, multidimensional
self-assessment questionnaire that has been validated for a
German-speaking population [56]. It covers five different
dimensions of fatigue (general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue).
Scores are derived by summing the answers (five-stage
Table 1 Assessments and instruments used in the PETRA study
Outcomes Instrument t0 t1 t2 t3 t4 t5 t6
Primary endpoint
Overall 2-year survival Medical log (ongoing assessment)
Secondary endpoints
2-year non-relapse mortality, median (disease-free) survival Medical log (ongoing assessment)
Quality of life EORTC QLQ30 / HDC-29 module X X X X X X X
Fatigue Multidimensional Fatigue Inventory (MFI) X X X X X X X
Muscle strength Isometric and isokinetic strength of representative
muscle groups for upper and lower extremity
measured at the IsoMed2000®
X X X X
Hand-Held-Dynamometer (isometric) X X X X X X X
Cardiorespiratory fitness CPET (VO2peak) X X X X
6-min Walk Test X X X X X X X
Body composition bioelectrical impedance analysis, weight, height X X X X X X X
Physical Activity Accelerometry X X X X X X
Depression CES-D X X X X X X X
Distress NCCN-Distress X X X X X X X
Locus of control KKG (German) X X X X X X X
Cognitive function Trail-making-test X X X X X X X
Common side-effects VAS, every week, later every 3 weeks
Biomarker Various methods (ELISA) X X X X X X X
Oxidative stress marker Analysed in urine samples X X X X X X X
Others
Socio-demographic factors Recording of date of birth, education, occupation,
familial situation, smoking, alcohol consumption
X X X
Medical history Recording of pre-existing diseases, therapies X
Treatment data Conditioning, complications X
Karnofsky Performance Score Physician rating X X X X X X X
Medication (immunosuppression, corticosteroids, analgesics) Recorded at each visit/phone call on a medication
log form
X X X X X X X
Physical activity history Physical activity in adolescence, pre-diagnosis, during,
and after intervention is recorded, including walking,
cycling, and sports activities
X X X X
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scale) of the appropriate items. Reference values of the
MFI scores are available from a representative sample of
the German population including 2,037 subjects [57]. The
use of the MFI is recommended in cancer patients [58].
Distress
Distress will be assessed with the Distress-Thermometer,
developed from the National Comprehensive Cancer
Network (NCCN) as a screening tool [59, 60]. The
Distress-Thermometer has already been validated in
stem cell transplantation patients [61].
Depression
Depressive symptoms are assessed with the 20-item
Center for Epidemiological Studies Depression Scale
(CES-D). The CES-D scale is a widely used validated self-
report instrument to measure current depressive symp-
tomatology and to identify possible cases of depressive
disorders, both in the general population and in patients
with cancer [62].
Locus of control
Locus of control is measured by a validated German 21-
item questionnaire Assessment of health and sickness locus
of control (KKG). It comprises 3 subscales, assessing in-
ternal, social external and fatalistic external locus of control
[63]. The questionnaire is based on the Multidimensional
Health Locus of Control Scale (MHLC) [64].
Cognitive function
The cognitive function (concentration, cognitive flexibility)
is estimated using the trail-making-test. This is a standard-
ized, reliable and valid measure used in neuropsychological
diagnostics [65, 66]. The test measures the time needed by
the participant to connect numbers and letters spread over
a sheet of paper in a logical sequence.
Biomarkers
Serum and PBMCs are derived from whole peripheral
blood samples, processed within 4 h after taking the
blood sample and stored at −80 °C or cryopreserved in
liquid nitrogen (PBMCs) for analyses of biomarkers.
Urine samples are collected for analyses of biomarkers
of oxidative stress, i.e. urinary F2-isoprostane and 8-oxo-
dG measured by chromatography-based methodology.
Blood samples are collected for analyses of biomarkers
of GvHD, i.e. inflammatory (e.g. IL-1, IL-4, IL-10, TNF-α)
and endothelial parameters (e.g. angiopoetin-2, thrombo-
modulin (sTM)) measured by ELISA.
Side-effects of cancer treatment
Severity and duration of GvHD will be recorded by
attending physicians every week according to the classi-
fication by Thomas et al. [67]. Furthermore, during allo-
HCT and up to day 100 after, common side effects like
nausea, diarrhea, appetite loss, pain, fatigue, concentra-
tion difficulties and anxiety are assessed weekly during
phone calls using a visual analogue scale. After day 100
until the end of intervention (day 365 after) patients are
questioned on these parameters during every phone call
(depending on clinical status every 2–4 weeks). Infec-
tions are documented via medical chart review.
Safety issues
Potential adverse events (AEs) and serious adverse events
(SAEs) causally related to the intervention or assessment
procedure will be recorded. Patients are informed about
contraindications for exercise sessions (thrombopenia,
bleeding, infections including fever, dizziness, strong nau-
sea/ vomiting, and strong pain) and advised to stop exer-
cising when they feel that symptoms get stronger.
Sample size
Sample size was chosen to achieve adequate statistical
power (1-β = 0.8) for detecting a difference between the
exercise and relaxation group with respect to two-year
overall survival (primary outcome). The calculation is
based on the two-year overall survival rates of our previ-
ous RCT (0.66 in the exercise group vs 0.49 in the con-
trol group) [35]. Accordingly, 128 participants per group
(total number = 256) are needed to achieve adequate
power to detect a significant (two-tailed α = 0.05) differ-
ence from Kaplan-Meier estimates tested for equality by
log-rank tests.
Participants and setting
All patients, scheduled for an allo-HCT at the Heidelberg
University Clinic are invited to participate in the PETRA
study. Inclusion criteria are age ≥18 years and the ability
to understand and follow the study protocol. Exclusion
criteria comprise contra-indications for progressive exer-
cise training, i.e. inability to walk or stand, instable bone
lesions, severe neurological deficiencies, severe cardiac or
cardiovascular diseases and severe pulmonary global
insufficiency.
Recruitment and randomization
All eligible patients scheduled for allo-HCT at the
University Hospital in Heidelberg are briefly informed
about the PETRA study during the preparation visit
(about 2–3 weeks before admission for allo-HCT) by
case-management. If interested, patients are then in-
formed in detail by the PETRA study coordinator. Upon
written informed consent, the patient is included in the
trial and scheduled for baseline assessment (t0), which
should be within 14 days prior to start of conditioning for
allo-HCT.
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After completion of the baseline assessments, the
participant is randomly allocated to one of the two inter-
vention groups. Allocation is done by the minimization
method [68] stratified by disease, age (< 40 / ≥ 40 years
of age), gender, remission state (CR/ no CR), and inten-
sity of conditioning (full/ doses reduced). Stratification is
used in the randomization process, as we anticipate
these variables to have major influence on the outcome.
Interventions
The training starts at the same day as the conditioning
treatment. Both intervention programs are performed
3–5 times per week for 12 months. During the first
phase (hospital stay for allo-HCT) participants perform
the program 3 times under supervision and guidance of
an experienced therapist, 2 times self-directed. During
the second phase (after discharge), patients perform
both interventions self-directed at home. Until assess-
ment on day 100 weekly phone calls in both groups will
allow for adaptation of the program and enhance motiv-
ation/ adherence, 3 training sessions per week are rec-
ommended. After day 100 assessment, phone calls will
take place every 2–3 weeks.
Exercise intervention
All patients receive an exercise manual with background
information (including contraindications for training, mo-
tivation), instructions for tailoring the training intensity
(depending on clinical status), descriptions for different
resistance exercises for the whole body and endurance
exercises. Patients receive stretch bands and free weights
for resistance exercises, for endurance exercises patients
have access to a stationary bicycle (patient room) and a
treadmill (hallway) during the inpatient period. We devel-
oped a self-rating instrument which helps patients to find
the appropriate exercise intensity (including RPE scale)
[13]. The exercise intervention complies with the ACSM
exercise guidelines for cancer survivors and healthy adults
and is progressed on an individual basis [6, 69]. A complete
resistance training session includes 6 to 10 exercises for
major upper and lower muscle groups and is recommended
2–3 times per week. Endurance training comprises bicyc-
ling or walking/jogging 3 times per week. Patients are en-
couraged to increase exercise intensity when they reach 3
sets of 12 repetitions for the resistance exercises or when
they feel less exhausted using the RPE-scale (target 12–14
for endurance exercise, 14–16 for resistance exercise) [70].
The exercise program is performed on a very individual
basis and includes also some psychological aspects e.g.
motivation, goal setting, dealing with barriers, and regular
feedback on physical performance data is given to pro-
mote adherence [71]. Adherence to FITT components
(frequency, intensity, type, timing) will be described
[72] to ensure correct interpretation of the findings.
Furthermore, it is possible to perform the training in
an appropriate sport/ exercise facility close to patients’
homes. Within the scope of the PETRA study we will
also develop a network called ‘OnkoActive’, which will
enable referral to specialized exercise facilities. Further-
more, within ‘OnkoActive’ an internet-based training
platform will be developed to support the home-based
intervention.
Relaxation intervention
The progressive muscle relaxation method according to
Jacobsen does not include any aerobic or muscle strength-
ening components [73]. Patients receive a manual with
background information, an audio CD with 2 different
versions (long/ short version) and a portable CD player.
Patients in the control group will receive the standard
physiotherapy program and will also have access to a bi-
cycle ergometer and treadmill during the inpatient period.
Data analysis
The main intervention effect will be assessed on the basis
of a Cox-regression analysis between exercisers and con-
trols (relaxation group) as defined at randomization,
regardless of exercise adherence, i.e. according to the
intent-to-treat principle.
The differences in secondary endpoints between groups
will be assessed using mixed models, which accounts for
repeated observations on the same subjects over time.
This method provides a more efficient estimate of the
intervention effect in pretest-post-test trials than trad-
itional methods [74]. Mixed models will also be used for
testing to which extent differences between the treatment
groups depend on training adherence, changes in muscle
strength, cardiorespiratory fitness, and body composition.
Normality assumptions will be checked and, if deviation
from normality is detected the data will be transformed
accordingly.
In addition, change in physical activity behavior post
intervention will be monitored on an explorative basis.
Discussion
Treating hematological malignant diseases with allo-HCT
is highly demanding for patients who experience numer-
ous side-effects and face a very high risk of severe treat-
ment related complications, such as GvHD and severe
infections, both in the short and long-term. In general,
survival rates after allo-HCT are relatively low.
Recently, our group demonstrated that there may be a
positive effect of exercise on survival after allo-HCT. In
our first RCT we observed a significant reduced total mor-
tality for the experimental group (12 vs. 28 %, p = .034)
and for NRM (4 vs. 13 %, p = .017). Furthermore, we
observed that physical fitness prior transplantation was
highly protective against NRM [35]. The cohort study by
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Wood et al. also suggests an association between fitness
level prior transplantation and risk of mortality [33], but a
small sample size of 22 patients and no use of multivariate
models hamper the interpretation of these results. Against
this background we designed the PETRA study. PETRA
will add to current knowledge on exercise in allo-HCT
patients with respect to several aspects: (1) Effect of year-
long exercise intervention on prognosis; (2) exercise effect
on side-effects and complications, e.g. physical perform-
ance, QoL, fatigue; (3) exercise effect on GvHD and
hematological/immunological reconstitution; and (4) sus-
tainability and long-term effects of exercise intervention.
Given the indication of reducing mortality in cancer
survivors by an appropriate physical active lifestyle, the
question about possible mechanisms occurs. Some evi-
dence suggests several potential mechanisms underlying
[30]. One discussed mechanism is inflammation [75].
Several trials reported that exercise can reduce C-reactive
protein (CRP), which is a marker of chronic inflammation
[76–78] and change Interleukin-6 (IL-6) levels. IL-6 pro-
duced by muscle fibers during and after exercise stimu-
lates the circulation of anti-inflammatory cytokines, such
as IL-1ra and IL-10 and inhibits the production of tumor
necrosis factor alpha (TNF-α) [79]. In a prospective
cohort study in breast cancer patients, elevated CRP and
serum amyloid A were associated with reduced overall
survival [80]. Furthermore, when exercise potentially can
influence parts of the immune system, the question arises,
if a GvHD reaction in allo-HCT patients can also be influ-
enced by exercise. To our knowledge, no intervention
study in humans investigated a possible association be-
tween exercise and severity of the major side-effect
GVHD. New results from mice experiments suggest that
physical exercise can have a positive impact on GvHD.
The researchers showed that endurance training (5 times
per week) in mice was beneficial with regard to overall
survival and also alters GvHD symptom severity. Further-
more, the authors revealed possible pathways for altering
GvHD by demonstrating that exercising mice had lower
levels of anti-inflammatory cytokines (IL-4 and TNF-α)
[81]. Based on these findings, we aim to investigate
whether exercise is able to alter GvHD severity in human
adults. We are further interested to elucidate other pos-
sible exercise pathways altering GvHD by investigation of
endothelial markers. Markers of interest are blood bio-
markers of inflammation and TNF-α as well as endothelial
markers and hepatocyte growth factor [82–85]. Natural
killer cells (NK-cells) have also been shown to modulate
acute GvHD, infections and recurrence [86, 87]. The posi-
tive effect of exercise on NK-cell activity in cancer patients
could already be shown in studies [88], and a review about
NK-cells and exercise suggests exercise as an adjunct
therapy to promote expansion of NK-cell subsets [89].
Interestingly, one RCT in allo-HCT patients could already
observe a positive effect of exercise during transplantation
process on lymphocyte count [90].
Additionally, restoring the function of the entire
haematological system after allo-HCT is an important
prognostic indicator [91, 92]. Therefore, we focus also
on exercise effects on haematological recovery after allo-
HCT. A potential positive effect on the haematological
system e.g. lymphocytes, haemoglobin could already be
shown [8, 90, 93].
A central secondary endpoint is cancer-related fatigue.
Fatigue is described as the most distressing side effect in
cancer treatment, however, the pathophysiology of fatigue
and the possible positive effect of exercise on its preven-
tion/therapy are not well understood [94]. Therefore, our
trial enables investigation of the effects of exercise on
immunologic parameters as well as on biomarkers of in-
flammation and oxidative stress as possible mediators of
fatigue [95, 96]. However, not only fatigue is a common
side-effect. As a consequence of longer periods of drug in-
take, e.g. immune suppression and antibiotics, patients
often suffer from nausea, diarrhea and further complaints.
Recent studies indicated a better symptom control in
exercising patients [97].
Our decision of choosing an intervention period of
one year was based on the consideration that the recov-
ery period after allo-HCT can take months to years.
However, even years after allo-HCT patients have an
increased risk to develop co-morbid conditions, e.g.
metabolic or cardiovascular diseases [22]. On one hand,
emerging research evidence indicates that these life style
diseases are associated with physical inactivity. On the
other hand, studies show that hematological cancer sur-
vivors are less likely to be physically active. Moreover,
changing exercise behavior requires longer, individually
adapted interventions. To enhance motivation and ad-
herence, the PETRA study uses goal setting methods,
and individual barriers are discussed during regular phone
calls. These components have been shown to improve
adherence [71]. Furthermore, PETRA helps patients to
integrate in an exercise facility close to their home or give
them the possibility to perform an internet-based training
program. All these efforts may help patients to change the
physical activity behavior in the long term. Finally, if dur-
ing or at the end of the exercise intervention beneficial
effects are detected, it is of interest whether those benefits
sustain over a longer period of time.
Strengths of the PETRA study are the rigorous study
design with a large sample size, adequately powered for
the primary endpoint survival, and a broad range of
assessments, including gold-standard methods for phys-
ical fitness and physical activity. Therefore, PETRA pro-
vides a unique opportunity to examine the interaction of
exercise/ physical activity on the haematological system
and GvHD reaction. A further strength is the choice of
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the control group (relaxation training). Previous exercise
RCT used typically usual care as comparison groups.
Thus, it is unclear to what extent the observed effects
are based on the physical exercise effect itself, or rather
on psycho-social factors related to social support or atten-
tion by the trainer. This factor is particularly important
when psychosocial outcomes are measured.
Conclusion
Previous studies in allo-HCT patients established first
evidence about beneficial effects of exercise interven-
tions on physical and psychosocial outcomes. However,
the focus changed to more clinically relevant endpoints,
e.g. prognosis. To our knowledge, no study has yet investi-
gated a possible effect of exercise on overall survival after
allo-HCT. Furthermore, there is a need for a better under-
standing of the physiological and psychological effects of
exercise and their biological mechanisms in patients dur-
ing and after allo-HCT. The PETRA study will provide a
comprehensive picture of the potential effects of exercise
during and after allo-HCT on overall survival, reducing
side-effects and complications, and improving quality of
life. We anticipate that our study will help to refine exer-
cise guidelines for allo-HCT patients.
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